Printer Friendly

Ionis Earns USD 5m with Licensure of Antisense Drug to Dynacure.

M2 PHARMA-November 10, 2017-Ionis Earns USD 5m with Licensure of Antisense Drug to Dynacure

(C)2017 M2 COMMUNICATIONS

- Carlsbad, California-based RNA-targeted therapeutics developer Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy to Strasbourg, France-based Dynacure, the companies said.

Ionis earned a USD 5m license fee in the form of Dynacure equity.

Dynacure will now assume all development and commercialization responsibilities for the program.

Under its collaboration agreement with Dynacure, Ionis is eligible to receive additional cash or equity of up to more than USD 205m in milestone payments.

In addition, Ionis is eligible to receive royalties on future product sales of the drug under this collaboration.

Ionis is focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, the company has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development.

Dynacure develops new treatments for patients suffering from serious orphan disorders. The company's first drug discovery program focuses on centronuclear myopathies, a rare debilitating disease affecting children and young adults.

The Dyn101 development program is based on the modulation of the Dynamin 2 protein expression through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 10, 2017
Words:240
Previous Article:Lunasin and Deanna Protocol Regimen Helps improve Quality of Life of Veterans with ALS.
Next Article:Entyvio Achieves Higher Rates of Deep Remission of Active Ulcerative Colitis than Placebo.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters